London, UK: Ark Therapeutics Group plc ('Ark') announces today
that it has signed an exclusive agreement with Flen Pharma, the private Belgian
wound care company, giving Ark the rights to market Flaminal(R), an
anti-microbial wound care gel, in the UK. Under the terms of the deal, Ark will
be responsible for reimbursement and conducting all sales and marketing
activities and will pay Flen Pharma a transfer price for the finished product.
Ark's existing sales force, which currently markets Kerraboot(R), a product for
diabetic and venous leg ulcers, will be used to promote Flaminal(R) in the UK.
